TMX-302

**TMX-302** is a **TLR7 partial agonist** developed by Telormedix as an investigational small molecule for treating inflammatory and autoimmune diseases, particularly **psoriasis**. It binds with high specificity to **Toll-like receptor 7 (TLR7)** on plasmacytoid dendritic cells, triggering anti-inflammatory responses to suppress T cell-mediated immune pathology. The compound was advanced through EU-funded preclinical projects (e.g., PAT) to develop oral and topical nanoparticle formulations optimized for bioavailability and skin penetration, using animal models mimicking human psoriasis; no clinical trial data for TMX-302 in psoriasis is available, and development appears limited to preclinical stages with no recent updates.[3][5][11][13]